PL3372229T3 - Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana - Google Patents

Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana

Info

Publication number
PL3372229T3
PL3372229T3 PL18169211T PL18169211T PL3372229T3 PL 3372229 T3 PL3372229 T3 PL 3372229T3 PL 18169211 T PL18169211 T PL 18169211T PL 18169211 T PL18169211 T PL 18169211T PL 3372229 T3 PL3372229 T3 PL 3372229T3
Authority
PL
Poland
Prior art keywords
methods
angelman syndrome
tonic inhibition
treating angelman
increasing tonic
Prior art date
Application number
PL18169211T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of PL3372229T3 publication Critical patent/PL3372229T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL18169211T 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana PL3372229T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP18169211.2A EP3372229B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating angelman syndrome
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
PL3372229T3 true PL3372229T3 (pl) 2021-10-04

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18169211T PL3372229T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
PL15803364T PL3151832T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15803364T PL3151832T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności

Country Status (20)

Country Link
US (11) US20150352085A1 (pl)
EP (3) EP3372229B1 (pl)
JP (4) JP2017516868A (pl)
AR (1) AR100772A1 (pl)
AU (4) AU2015269667B2 (pl)
CA (1) CA2950845C (pl)
CY (2) CY1124366T1 (pl)
DK (2) DK3151832T3 (pl)
ES (2) ES2876350T3 (pl)
HR (2) HRP20210901T1 (pl)
HU (2) HUE055400T2 (pl)
IL (2) IL249287B (pl)
LT (2) LT3372229T (pl)
MX (2) MX391502B (pl)
PL (2) PL3372229T3 (pl)
PT (2) PT3372229T (pl)
RS (2) RS62006B1 (pl)
SI (2) SI3372229T1 (pl)
SM (2) SMT202100340T1 (pl)
WO (1) WO2015187851A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6634626B2 (ja) 2013-11-05 2020-01-22 エレーナ モロカノヴァＥｌｅｎａ ＭＯＬＯＫＡＮＯＶＡ 受容体およびイオンチャネルの位置特異的サブタイプの調節のためのナノ構造物複合体
ES2876350T3 (es) 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) * 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제
WO2021127308A1 (en) * 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
JP2026506097A (ja) * 2023-02-17 2026-02-20 オービッド・セラピューティクス・インコーポレイテッド 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20080269278A1 (en) 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
ES2876350T3 (es) 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
KR20240160666A (ko) * 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
AU2024202604A1 (en) 2024-05-09
HRP20210902T1 (hr) 2021-09-17
MX2016016136A (es) 2017-07-05
US20170273956A1 (en) 2017-09-28
EP3151832B1 (en) 2021-03-24
PT3151832T (pt) 2021-06-15
MX391502B (es) 2025-03-21
DK3151832T3 (da) 2021-06-14
RS62007B1 (sr) 2021-07-30
IL249287B (en) 2021-03-25
US9801864B2 (en) 2017-10-31
US20170087133A1 (en) 2017-03-30
US20180015076A1 (en) 2018-01-18
CA2950845C (en) 2023-04-25
WO2015187851A1 (en) 2015-12-10
JP2023123442A (ja) 2023-09-05
US9744159B2 (en) 2017-08-29
AU2022200085A1 (en) 2022-02-03
SI3151832T1 (sl) 2021-08-31
HRP20210901T1 (hr) 2021-09-17
US20150352085A1 (en) 2015-12-10
AR100772A1 (es) 2016-11-02
US20160228418A1 (en) 2016-08-11
CY1124368T1 (el) 2022-07-22
US20170071917A1 (en) 2017-03-16
LT3151832T (lt) 2021-07-12
LT3372229T (lt) 2021-07-12
US20220016091A1 (en) 2022-01-20
US20230051859A1 (en) 2023-02-16
EP3372229A1 (en) 2018-09-12
US11278529B2 (en) 2022-03-22
HUE055400T2 (hu) 2021-11-29
RS62006B1 (sr) 2021-07-30
EP3151832A1 (en) 2017-04-12
ES2876350T3 (es) 2021-11-12
CY1124366T1 (el) 2022-07-22
AU2015269667A1 (en) 2016-12-22
CA2950845A1 (en) 2015-12-10
IL268960A (en) 2019-10-31
EP3372229B1 (en) 2021-03-24
AU2020217342B2 (en) 2021-10-07
MX380868B (es) 2025-03-12
AU2015269667B2 (en) 2020-07-30
IL249287A0 (en) 2017-02-28
DK3372229T3 (da) 2021-06-14
HUE055155T2 (hu) 2021-11-29
PL3151832T3 (pl) 2021-10-25
SMT202100343T1 (it) 2021-07-12
MX2020012404A (es) 2022-04-11
SI3372229T1 (sl) 2021-09-30
IL268960B (en) 2021-05-31
EP3151832A4 (en) 2018-01-17
ES2875742T3 (es) 2021-11-11
JP2017516868A (ja) 2017-06-22
AU2020217342A1 (en) 2020-08-27
PT3372229T (pt) 2021-06-17
US20250025448A1 (en) 2025-01-23
EP3795156A1 (en) 2021-03-24
US9446028B2 (en) 2016-09-20
JP2021178836A (ja) 2021-11-18
US20160038469A1 (en) 2016-02-11
JP2020063264A (ja) 2020-04-23
US9339495B2 (en) 2016-05-17
US20180303805A1 (en) 2018-10-25
SMT202100340T1 (it) 2021-07-12

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
SMT202100343T1 (it) Metodi per aumenare l'inibizione tonica e trattare la sindrome di angelman
ZA202006746B (en) Methods of treatment
IL259801A (en) ezh2 inhibitors and methods of using them
IL250415B (en) Antibodies against pd-l and methods of using them
SG11201803213XA (en) Glycan-interacting compounds and methods of use
ZA201706257B (en) Treatment of wood
IL273932A (en) Methods of treatment and prevention of viral infection
GB2539390B (en) Security devices and methods of manufacture thereof
IL282482A (en) Variants of protoxin-II and methods of use
GB201514760D0 (en) Compounds and method of use
IL282508A (en) Variants of protoxin-II and methods of use
GB201520900D0 (en) Devices and methods for treatment of ventilator associated dysphagia
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
PT3397364T (pt) Elementos estruturados e métodos de utilização
GB201416832D0 (en) Methods of treatment
GB201413530D0 (en) Treatment and prevention of malaria
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL252779B (en) Prevention and treatment of inflammatory diseases
PL3268376T3 (pl) Inhibitory enolazy i sposoby leczenia je wykorzystujące
GB201417248D0 (en) Compostion and methods of treatment
GB201512139D0 (en) Methods of treatment
GB201416797D0 (en) Contianer and method of use thereof